ArticleMolecular cell2018
Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind.
Article in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.Nucleic acids research · 2025Article
- Unraveling the nexus: Genomic instability and metabolism in cancer.Cell reports · 2025Review
- LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers.Molecular cancer therapeutics · 2025Article
- 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer.Nature communications · 2024Article
- Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.Molecular carcinogenesis · 2024Article
- Review
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Leveraging the replication stress response to optimize cancer therapy.Nature reviews. Cancer · 2023Review
- PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.International journal of molecular sciences · 2022Review
- Opinion: PARP inhibitors in cancer-what do we still need to know?Open biology · 2022Review
- GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.Molecular cancer research : MCR · 2022Article
- Olaparib Induces RPL5/RPL11-Dependent p53 ActivationFrontiers in oncology · 2022Article
- PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.Frontiers in pharmacology · 2022Review
- Review
- TheGenes & development · 2021Article
- Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.Molecular cell · 2021Article
- Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.Experimental & molecular medicine · 2021Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Two recent studies implicate PARP as sensors of incompletely processed Okazaki fragments, changing our view about how single-strand breaks arise in unperturbed cells. Unligated Okazaki fragments may trigger homologous recombination-mediated repair and underpin genome instability in BRCA1/BRCA2-deficient cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.